Breast (Feb 2021)
Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
- Andreas Schneeweiss,
- Johannes Ettl,
- Diana Lüftner,
- Matthias W. Beckmann,
- Erik Belleville,
- Peter A. Fasching,
- Tanja N. Fehm,
- Matthias Geberth,
- Lothar Häberle,
- Peyman Hadji,
- Andreas D. Hartkopf,
- Carsten Hielscher,
- Jens Huober,
- Eugen Ruckhäberle,
- Wolfgang Janni,
- Hans Christian Kolberg,
- Christian M. Kurbacher,
- Evelyn Klein,
- Michael P. Lux,
- Volkmar Müller,
- Naiba Nabieva,
- Friedrich Overkamp,
- Hans Tesch,
- Elena Laakmann,
- Florin-Andrei Taran,
- Julia Seitz,
- Christoph Thomssen,
- Michael Untch,
- Pauline Wimberger,
- Rachel Wuerstlein,
- Bernhard Volz,
- Diethelm Wallwiener,
- Markus Wallwiener,
- Sara Y. Brucker
Affiliations
- Andreas Schneeweiss
- National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Johannes Ettl
- Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
- Diana Lüftner
- Charité University Hospital, Berlin, Campus Benjamin Franklin, Department of Hematology, Oncolo0gy and Tumour Immunology, Berlin, Germany
- Matthias W. Beckmann
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany
- Erik Belleville
- ClinSol GmbH & Co KG, Würzburg, Germany
- Peter A. Fasching
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany; Corresponding author. Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen EMN, Friedrich Alexander University of Erlangen–Nuremberg, Universitätsstrasse 21–23, 91054, Erlangen, Germany.
- Tanja N. Fehm
- Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Germany
- Matthias Geberth
- Gynäkologische Praxisklinik am Rosengarten, Mannheim, Germany
- Lothar Häberle
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany; Biostatistics Unit, Erlangen University Hospital, Department of Gynecology and Obstetrics, Erlangen, Germany
- Peyman Hadji
- Frankfurt Center of Bone Health Frankfurt, Germany
- Andreas D. Hartkopf
- Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
- Carsten Hielscher
- gSUND Gynäkologie Kompetenzzentrum Stralsund, Stralsund, Germany
- Jens Huober
- Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
- Eugen Ruckhäberle
- Department of Gynecology and Obstetrics, Düsseldorf University Hospital, Germany
- Wolfgang Janni
- Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm, Germany
- Hans Christian Kolberg
- Marienhospital Bottrop, Bottrop, Germany
- Christian M. Kurbacher
- Gynecology I (Gynecologic Oncology), Gynäkologisches Zentrum Bonn Friedensplatz, Bonn, Germany
- Evelyn Klein
- Department of Obstetrics and Gynecology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany
- Michael P. Lux
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany
- Volkmar Müller
- Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
- Naiba Nabieva
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany
- Friedrich Overkamp
- Oncologianova GmbH, Recklinghausen, Germany
- Hans Tesch
- Oncology Practice at Bethanien Hospital, Frankfurt, Germany
- Elena Laakmann
- Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg, Germany
- Florin-Andrei Taran
- Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
- Julia Seitz
- National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
- Christoph Thomssen
- Department of Gynecology, Martin Luther University of Halle-Wittenberg, Halle (Saale), Germany
- Michael Untch
- Department of Gynecology and Obstetrics, Helios Clinics Berlin Buch, Berlin, Germany
- Pauline Wimberger
- National Center for Tumor Diseases and Department of Gynecology and Obstetrics, Dresden University Hospital, Dresden, Germany
- Rachel Wuerstlein
- Department of Gynecology and Obstetrics, Breast Center, and CCC Munich, Munich University Hospital, Germany
- Bernhard Volz
- Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, Germany
- Diethelm Wallwiener
- Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
- Markus Wallwiener
- Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany
- Sara Y. Brucker
- Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany
- Journal volume & issue
-
Vol. 55
pp. 138 – 139
